Anthem Biosciences, a Karnataka-based innovation-led CRDMO, has announced its IPO price band of ₹540–₹570 per share. The ₹3,395 crore public issue will open on July 14, 2025, and close on July 16. The issue is a complete offer for sale with shares set to list on both NSE and BSE.
Anthem Biosciences Ltd, a leading innovation-driven Contract Research, Development, and Manufacturing Organization (CRDMO), headquartered in Karnataka, India, has announced the launch of its ₹3,395 crore Initial Public Offering (IPO). The IPO will open for public subscription from July 14 to July 16, 2025, with the anchor book opening on July 11, 2025.
The price band for the IPO has been fixed at ₹540 to ₹570 per share, with a face value of ₹2 each. The public issue is entirely an Offer for Sale (OFS) of 5.96 crore equity shares by existing shareholders. Therefore, the company will not receive any direct proceeds from the offering.
The IPO will be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE), with a tentative listing date of July 21, 2025. Post-closure, allotment is expected to be finalized on July 17, with refunds and share credits processed by July 18.
The offering is structured with 50% reserved for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 35% for Retail Investors. An additional ₹8.25 crore worth of equity shares have been reserved for eligible employees. Retail investors can apply in lots of 26 shares, requiring a minimum investment of ₹14,820.
Anthem Biosciences specializes in fermentation-based Active Pharmaceutical Ingredients (APIs) including enzymes, peptides, probiotics, biosimilars, and nutritional actives. The company operates two integrated manufacturing facilities in Karnataka — Unit I in Bommassandra and Unit II in Harohalli — with a combined annual capacity of 270 kL for custom synthesis and 142 kL for fermentation.
Among its industry peers are Sai Life Sciences, Syngene International, Suven Life Sciences, and Divi’s Laboratories.
The IPO is being managed by JM Financial Ltd, Citigroup Global Markets India, J P Morgan India, and Nomura Financial Advisory & Securities (India), while KFin Technologies is the registrar for the issue.
This IPO underscores investor interest in India’s growing pharmaceutical manufacturing and research sector, especially in the CRDMO segment.
